Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term Debt
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed N.V (MYNZ) Total Liabilities: 2020-2025

Historic Total Liabilities for Mainz Biomed N.V (MYNZ) over the last 1 years, with Jun 2025 value amounting to $7.3 million.

  • Mainz Biomed N.V's Total Liabilities fell 42.18% to $7.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $48.5 million, marking a year-over-year decrease of 5.05%. This contributed to the annual value of $7.2 million for FY2024, which is 40.86% down from last year.
  • Latest data reveals that Mainz Biomed N.V reported Total Liabilities of $7.3 million as of Q2 2025, which was up 1.25% from $7.2 million recorded in Q4 2024.
  • Mainz Biomed N.V's Total Liabilities' 5-year high stood at $14.5 million during Q3 2023, with a 5-year trough of $3.7 million in Q4 2021.
  • Over the past 3 years, Mainz Biomed N.V's median Total Liabilities value was $12.2 million (recorded in 2023), while the average stood at $11.1 million.
  • As far as peak fluctuations go, Mainz Biomed N.V's Total Liabilities skyrocketed by 267.57% in 2023, and later tumbled by 42.18% in 2025.
  • Quarterly analysis of 5 years shows Mainz Biomed N.V's Total Liabilities stood at $3.7 million in 2021, then soared by 67.00% to $6.1 million in 2022, then surged by 97.88% to $12.2 million in 2023, then tumbled by 40.86% to $7.2 million in 2024, then tumbled by 42.18% to $7.3 million in 2025.
  • Its Total Liabilities stands at $7.3 million for Q2 2025, versus $7.2 million for Q4 2024 and $12.6 million for Q2 2024.